← Leaderboards
Douglas A. Simonetto
Mayo Clinic Rochester
$942,636
Attributed
$1,885,271
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $441.1K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,885,271 · 2
By mechanism
U01$1,885,271 · 2
Top collaborators
- Vijay H Shah10 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Richard L. Ehman$9,140,218
- Sundeep Khosla$91,221,003
- David O Warner$17,454,427
- Meng Yin$9,336,704
- Shigao Chen$9,672,228
Others in their field
Other Emerging Leaders on “Clinical Research”
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Lynn Briscoe · Leidos Biomedical Research, Inc.$319,807,684
- Chanza Baytop · Westat, Inc.$271,217,917
Research focus
Clinical ResearchMortalityPlacebosSuccessPrimary EndpointSafetyLiverNovel TherapeuticsRandomizedSecondary EndpointTherapeutic DevelopmentConduct Clinical TrialsResearch PersonnelCessation Of LifeFollow-UpFutureClinicTreatment EfficacyBaseCardiovascular SystemAntioxidantsAntimicrobialBiological Specimen BanksAlcoholic Hepatitis
Grant awards (10)
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$397,500
U01 · FY2025 · DK
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$239,180
U01 · FY2024 · DK
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$210,405
U01 · FY2023 · DK
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$297,083
U01 · FY2022 · DK
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2022 · AA
Liver Cirrhosis Network: Clinical Research Center - Mayo Clinic$366,103
U01 · FY2021 · DK
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2021 · AA
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2020 · AA
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2019 · AA
Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis$75,000
U01 · FY2018 · AA